Daniel S. Lorrain's most recent trade in Contineum Therapeutics Inc. - Ordinary Shares - Class A was a trade of 3,000 Class A Common Stock done at an average price of $14.8 . Disclosure was reported to the exchange on Feb. 3, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Contineum Therapeutics Inc (Class A) | Daniel S. Lorrain | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 14.82 per share. | 03 Feb 2026 | 3,000 | 157,222 | - | 14.8 | 44,469 | Class A Common Stock |
| Contineum Therapeutics Inc (Class A) | Daniel S. Lorrain | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 15.25 per share. | 03 Feb 2026 | 1,170 | 156,052 | - | 15.2 | 17,837 | Class A Common Stock |
| Contineum Therapeutics Inc (Class A) | Daniel S. Lorrain | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2026 | 160,000 | 160,000 | - | - | Stock Option (right to buy) | |
| Contineum Therapeutics Inc (Class A) | Daniel S. Lorrain | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2026 | 6,500 | 6,500 | - | - | Stock Option (right to buy) | |
| Contineum Therapeutics Inc (Class A) | Daniel S. Lorrain | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 10.35 per share. | 05 Jan 2026 | 3,670 | 160,722 | - | 10.3 | 37,978 | Class A Common Stock |
| Contineum Therapeutics Inc (Class A) | Daniel S. Lorrain | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 11.13 per share. | 05 Jan 2026 | 500 | 160,222 | - | 11.1 | 5,565 | Class A Common Stock |
| Contineum Therapeutics Inc (Class A) | Daniel S. Lorrain | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 12.23 per share. | 23 Dec 2025 | 4,170 | 164,392 | - | 12.2 | 51,009 | Class A Common Stock |
| Contineum Therapeutics Inc (Class A) | Daniel S. Lorrain | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 110,000 | 110,000 | - | - | Stock Option (right to buy) | |
| Contineum Therapeutics Inc (Class A) | Daniel S. Lorrain | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 3,700 | 3,700 | - | - | Stock Option (right to buy) | |
| Contineum Therapeutics Inc (Class A) | S. Lorrain Daniel | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 16.02 per share. | 25 Nov 2024 | 1,010 | 168,562 | - | 16.0 | 16,177 | Class A Common Stock |
| Contineum Therapeutics Inc (Class A) | Daniel S. Lorrain | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 16.37 per share. | 18 Nov 2024 | 6,091 | 169,671 | - | 16.4 | 99,733 | Class A Common Stock |
| Contineum Therapeutics Inc (Class A) | Daniel S. Lorrain | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 17.05 per share. | 18 Nov 2024 | 99 | 169,572 | - | 17.1 | 1,688 | Class A Common Stock |
| Contineum Therapeutics Inc (Class A) | Daniel S. Lorrain | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2024 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Contineum Therapeutics Inc (Class A) | Daniel S. Lorrain | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2024 | 3,700 | 3,700 | - | - | Stock Option (right to buy) |